Does Nitrofurantoin (Macrobid) exacerbate Clostridioides difficile (C. diff) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

Clostridium difficile-associated diarrhea: Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including nitrofurantoin, and may range in severity from mild diarrhea to fatal colitis. The use of nitrofurantoin may exacerbate Clostridioides difficile (C. diff) infection, as it can alter the normal flora of the colon leading to overgrowth of C. difficile.

  • Key points:
    • CDAD can range from mild diarrhea to fatal colitis
    • C. difficile produces toxins A and B which contribute to the development of CDAD
    • Hypertoxin producing strains of C. difficile cause increased morbidity and mortality
    • CDAD must be considered in all patients who present with diarrhea following antibiotic use 1

From the Research

Nitrofurantoin and C. diff Infection

  • The relationship between Nitrofurantoin (Macrobid) and Clostridioides difficile (C. diff) infection is complex, with some studies suggesting a potential link between the use of Nitrofurantoin and an increased risk of C. diff infection 2, 3.
  • A 2022 study found that Nitrofurantoin was associated with C. diff infection, particularly among older patients with risk factors for the infection, with an adjusted odds ratio of 3.05 (95% CI, 1.92 to 4.84) 2.
  • Another study from 2021 found that ciprofloxacin had a higher risk of C. diff infection compared to Nitrofurantoin, with an adjusted relative risk of 1.89 (95% CI, 1.45 to 2.68) 3.
  • However, it is essential to note that the risk of C. diff infection is not unique to Nitrofurantoin and can be associated with the use of various antibiotics, including clindamycin, cephalosporins, and fluoroquinolones 4, 5, 6.

Comparative Risks of Antibiotics

  • The comparative risks of different antibiotics for C. diff infection have been studied, with some antibiotics found to have a higher risk than others 2, 3, 6.
  • A 2022 study found that clindamycin, cefdinir, cefuroxime, and fluoroquinolones had a higher risk of C. diff infection compared to doxycycline, while Nitrofurantoin had a lower risk but still a significant association with C. diff infection 2.
  • Another study from 2021 found that the risk of C. diff infection increased with the duration of antibiotic use, with longer courses of antibiotics associated with a higher risk of infection 3.

Clinical Implications

  • The use of Nitrofurantoin and other antibiotics should be judicious and based on careful consideration of the potential risks and benefits, particularly in patients with risk factors for C. diff infection 4, 2, 5, 3, 6.
  • Antimicrobial stewardship programs that promote the responsible use of antibiotics are essential for reducing the risk of C. diff infection and other healthcare-associated infections 2, 6.

References

Research

Antibiotic Prescribing Choices and Their Comparative C. Difficile Infection Risks: A Longitudinal Case-Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021

Research

Clostridium difficile infection after antibiotic use.

JAAPA : official journal of the American Academy of Physician Assistants, 2020

Research

Antimicrobial-associated risk factors for Clostridium difficile infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.